Introduction
Monitoring the benefits and risks of vaccines is a complex and critical activity that involves multiple participants. Decisions to be made at the planning stage are numerous: definition of research objectives, specification of research outcomes, initiation of collaborations, allocation of resources, composition of teams, definition of roles and responsibilities, agreement on study designs, data sources, statistical plan, quality requirements and timelines, and processes for agreeing on the interpretation and reporting of the results. This can be particularly challenging where rapid action needs to be taken and a (updated) benefit/risk assessment is needed within short timelines. The 2009 (H1N1) flu pandemic threw light on the limited capacity to meet this challenge at the European level and to rapidly collect and analyse post-marketing data on vaccine exposure, safety and effectiveness. Following the authorisation of the first H1N1 influenza vaccines in Europe in September and October 2009, the core risk management plan adapted to the H1N1 strain included the definition of adverse events of special interests (AESIs), recommendations for observed-to-expected analysis for signal detection and requests to vaccine manufacturers for post-authorisation safety studies [1, 2] . However, the lack of a system to collect vaccination statistics at European level and background incidence rates for several AESIs led regulators to compile exposure data through ad-hoc surveys and to rely on assumptions for the expected rates of adverse drug reactions, which provided a wide range of possible values for the Standardized Morbidity Ratio (SMR) for the same set of data [2] . European data for background incidence rates for AESIs became available in December 2009 and January 2010, after the peak of the vaccination campaign [3] [4] [5] . Preliminary data from an industry-sponsored safety study were also available in January 2010, the first results of epidemiological studies conducted in Europe were made public at the end of August 2010, once the pandemic was over [6, 7] and estimates of vaccine effectiveness were published relatively late after the vaccination campaign. Those from the large I-MOVE European network were published in January 2011 [8] , although preliminary reports were available earlier to some regulatory and public health authorities. The main issue limiting the capacity for a timely collection, analysis and reporting of data was identified as the lack of a formal established European infrastructure providing rapid access to available data sources on large populations and supporting collaborations and common approaches for data collection [1, 2, 9] . In addition, lessons learnt from the pandemic underlined the difficulties to establish efficient interactions between multiple stakeholders (regulators, public health agencies, vaccine manufacturers), insufficient coordination of communication activities among interested parties, regulatory requirements unknown to other concerned bodies than vaccine manufacturers, disparate access to relevant data sources, concerns about possible or actual conflicts of interest and lack of mechanisms for the funding of studies [1, 9] . On the basis of these findings, the Innovative Medicines Initiative framework [10] was used in 2013 to set up the Accelerated Development of Vaccine benefit-risk Collaboration in Europe, (ADVANCE) [11] , a publicprivate consortium to work towards the vision of ''An efficient and sustainable infrastructure for rapid and integrated monitoring of post-approval benefit/risk of vaccines under clear governance rules meeting the common interest of all main stakeholders". Such a framework would allow regulators, public health authorities and vaccine manufacturers to make fast, informed decisions regarding vaccination strategies. To support effective collaborations and clear governance for the conduct of studies, a best practice guidance would include a code of conduct and recommendations for governance models, quality management and communication. Guidelines on the planning and conduct of pharmacoepidemiological studies already exist at national and international levels and were reviewed to identify whether they fulfil the needs of ADVANCE for a structured guidance applicable to every step of the conduct of collaborative vaccine studies. This field has a number of key characteristics such as focus on preventive health care, potentially large exposed populations in all age groups, a limited number of vaccine manufacturers, a broad range of concerned stakeholders (including public health authorities, regulatory authorities, vaccine manufacturers, academic institutions, health care professionals, vaccinated individuals and the public) and high attention to actual or perceived potential conflicts of interest. Such guidance should also serve the needs of public health surveillance, which requires the same level of scientific standards and transparency as in research. This article presents the ADVANCE Code of Conduct developed in this context.
Method

The ADVANCE project
ADVANCE revolves around three pillars needed for the intended framework: data sources (WP3), methods (WP4) and best practice mechanisms (WP1) (Fig. 1) . These pillars are strengthened by leverage of existing results, initiatives and projects, through synergetic collaboration (WP2), refined and validated through selected proof of concept studies (WP5) and leading to blueprint or model for benefit-risk monitoring of vaccines in Europe (WP7). WP6 provides the necessary coordination, management and communication backbone of the project. The ADVANCE Code of Conduct is part of best practice mechanisms to be developed by WP1.
Guiding principles
The ADVANCE Code of Conduct was developed on the basis of a core set of guiding principles [12] . In a first step, a survey was conducted among the ADVANCE consortium to assess what guiding values were considered the most important ones for the planning, initiation, design, conduct and reporting of post-marketing vaccine benefit-risk monitoring activities. The survey was conducted during a consortium general assembly with 47 attendees from different stakeholders (15 public health institutes, 10 academia, 6 regulatory agencies, 11 vaccine manufacturers, and 5 other groups). The survey helped identify guiding principles and topics to be addressed in the code of conduct.
Review of existing guidelines
In a second step, existing guidelines were identified and selected through consultation of ADVANCE consortium members, screening of the ENCePP Guide on Methodological Standards in Pharmacoepidemiology [13] , literature search and screening of the reference lists of retrieved documents in order to identify whether any current guideline would fit the needs for recommendations.
Development of the ADVANCE Code of Conduct
Each guideline was reviewed by two members of ADVANCE WP1 who extracted relevant recommendations for the predefined topics. For each topic, all recommendations were reviewed and either removed or kept and reworded as necessary. New recommendations were developed as needed. The resulting draft code of conduct was published on the ADVANCE website for a public consultation outside ADVANCE from 29 September to 15 November 2015. The call for comments was disseminated as widely as possible among relevant learned societies and individual experts. The text was revised based on the comments received.
In the course of the development of the code of conduct, the concept of the study team emerged as a core element of every study to endorse key roles and responsibilities. It was therefore developed simultaneously to the code of conduct.
Results
Guiding principles
Among the 14 candidate values initially identified (science, ethics, improving public health, excellence, integrity, transparency, open dialogue, independence, partnership, trust, reliability, respect, accountability, commitment), those ranking first overall in the survey of consortium partners were best science (''benefitrisk monitoring should rapidly deliver the best evidence possible on the research questions, applying the appropriate scientific methods with integrity"), strengthening public health (''all decisions should be guided by the extent to which they help to improve health at individual and population levels") and transparency (''key decisions and their rationale, the choice, design and conduct of the study, the interpretation of results, funding sources, roles of each participant and declarations of interests should be disclosed"). These three principles were also ranked first by representatives from public health institutes and academia, and any two of them were ranked first by representatives from other groups. Independence and ethics appeared only in the top three values selected by representatives of the regulators and vaccine manufacturers group, respectively (further information on this survey is available in a separate document [14] ). The principles of best science, strengthening public health and transparency were used to guide the identification of topics to be addressed in the ADVANCE Code of Conduct and the development of the recommendations.
Review of guidelines
A total of 44 guidelines and documents were identified from the literature review and suggestions provided during the public consultation. From these, 31 were considered relevant to provide useful information on at least one topic of the ADVANCE Code of Conduct. They are listed in the reference section of Appendix A. Among widely used guidelines in pharmacoepidemiology, the Code of Conduct [15] of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) provides standards for scientific independence and transparency of research that require registration of the study (with the study protocol and abstract of study results) in the EU Post-Authorisation Studies (PAS) Register [16] and making other study documentation available upon reasoned justification. As one of the provisions is that no person with a financial, commercial or personal interest in a particular study outcome shall take part in any study activity once the protocol has been finalised, it does not provide guidance for the conduct of collaborative studies involving multiple partners during the whole research process (be they regulatory authorities, public health authorities, academic institutions or vaccine manufacturers). It was therefore not considered comprehensive enough to meet the objectives of ADVANCE but its core principles of scientific independence and transparency were integrated into the ADVANCE Code of Conduct. Other important guidance includes the Good Pharmacoepidemiology Practices (GPP) of the International Society for Pharmacoepidemiology (ISPE) [17] and the Good Epidemiology Practice (GEP) of the International Epidemiological Association (IEA) [18] . The GPP proposes practices and procedures that should be considered to help ensure the quality and integrity of pharmacoepidemiological research, including detailed guidance for protocol development, roles and responsibilities, study conduct, communication, reporting of adverse events and archiving. The GEP addresses four general ethical principles for research (Autonomy, Beneficence, Non-maleficence and Justice) and proposes rules for good research behavior in relation to working with personal data, data documentation, publication, exercise of judgment and scientific misconduct. The GPP and the GEP do not address all topics to be covered by the ADVANCE Code of Conduct but they were used as an important source of guidance.
The ADVANCE Code of Conduct
During the public consultation, a total of 386 comments on the draft code of conduct were received from 20 organisations and individuals, including from ISPE, the ENCePP network, patients' and health care professionals' associations and vaccine manufacturers. The comments are available upon request to the corresponding author.
The resulting ADVANCE Code of Conduct includes 45 recommendations in 10 topics: Scientific integrity, Scientific independence, Transparency, Conflicts of interest, Study protocol, Study report, Publication, Subject privacy, Sharing of study data and Research contract (Appendix A). For each topic, it includes a definition, a list of recommendations and a list of source guidelines or publications supporting the recommendations and suggested as additional reading. The text distinguishes two levels of recommendations: 28 are considered critical and should be applied in all studies (''must") and 17 should be considered for all studies but may be less critical for the study governance (''should"). In case of public health crisis requiring faster conduct of a study, investigators may focus on recommendations with a ''must". The recommendations are listed for each topic by their ''must" and ''should" status in Table 1 and described in Appendix A.
The concept of the study team is presented in Appendix B. A study team should be established at the initiation of each study with the mandate to ensure that decisions taken during the study follow two key principles: scientific integrity -to ensure the highest quality of evidence is generated by the study -and transparencyto allow stakeholders from within or outside the study team to assess the background and reasoning for the decisions taken.
Discussion
Guiding principles may provide a solid foundation for the multiple decisions that need to be taken at all stages of the planning, design, conduct and reporting of vaccine studies [12] . The three core and common principles of best science, strengthening public health and transparency have been adopted by the ADVANCE consortium to form the backbone for the development of a detailed, comprehensive and stand-alone set of recommendations aiming to facilitate collaboration between multiple partners of collaborative studies in the field of vaccine benefit-risk monitoring. The ADVANCE Code of Conduct was developed and agreed by a wide range of different organisations: regulatory and public health authorities (including the European Medicines Agency and the European Centre for Disease Prevention and Control), vaccine manufacturers and academic organisations. It should be adopted in all studies and it should be adopted entirely and by all individuals and organisations involved in the study, provided that compliance with the applicable regulatory requirements and legislation can be maintained.
It is believed that its adoption by all partners involved in a study will facilitate and speed-up the initiation, design, conduct and reporting of studies by avoiding lengthy discussions on principles of collaborations and on contractual agreements. It is recommended that adoption of the ADVANCE Code of Conduct should be stated in the study protocol, study report and publications and journal editors are encouraged to use it as an indication that good principles of public health, science and transparency were followed throughout the study.
With 45 recommendations, the ADVANCE Code of Conduct is a comprehensive document that can be seen to be complex, and this perception may be a limitation for its adoption in studies with few participants and simple procedures. We are convinced, however, that its principles are universal and could be applied not only to studies on the benefit-risk of vaccines but also to those on drugs. The implementation of the ADVANCE Code of Conduct will be monitored through a review of vaccine post-authorisation safety and effectiveness studies submitted to regulatory and public health authorities, review of protocols of non-interventional studies registered in the EU PAS Register and search for statements on its use in studies published in scientific journals. Its implementation in each study can also be part of a structured monitoring by external bodies such as scientific committee or ethical committee. The experience will show whether the ADVANCE Code of Conduct contributes to the facilitation of vaccine studies by improving interactions between partners, supporting access to observational 
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Disclaimer
The views expressed in this article are those of the authors only and not of their respective institution or company. 3. The study team is responsible and accountable for the integrity and accuracy of its work. The study team members must adhere to the IEA Good epidemiological practice [2] and the ISPE Good pharmacoepidemiological practices [3] without exception. They must ensure that its work is performed objectively, using the most appropriate methodology. The research must be factual, transparent and designed objectively to appropriately answer the research question.
Additional reading: [4-10]
Scientific independence
Definition
Scientific independence means that all decisions on scientific aspects of the research are based on scientific grounds without undue influence of any financial, commercial, institutional or personal interest in a particular outcome of the research. These scientific aspects include the framing of the research question, its translation into a study design and the analysis, interpretation and dissemination of the research.
Recommendations
4. The study design, methods of data collection, data analysis, interpretation of the results, study report and publications must be based only on robust scientific criteria without undue influence of any financial, commercial, institutional or personal interest in a particular outcome of the research. 5. Autonomy of the study team members for making scientific decisions related to epidemiological research within their own organisation should be documented. 6. Fulfilling the following recommendations is necessary to safeguard scientific independence, in particular: Clear and transparent roles and responsibilities for each party as defined in the research contract, providing the study team with the responsibility for all decisions on scientific aspects of the study (study design, methods of data collection, data analysis, interpretation of the results, study report and publications) and allowing consultation of other parties on important study documents such as the study protocol, study report and manuscripts. Peer-review process with external experts or an external advisory board for important study documents such as the study protocol and study report; comments should be made available to all parties involved in the study. Protocol posting on public website before study data collection or extraction commences. Disclosure of all funding sources, all affiliations and all roles in the study; declaration of interests provided by all members of the study team.
Additional reading: [3, [11] [12] [13] [14] 3. Transparency
Definition
Transparency means having study information accessible to those having an interest in the study results, either as individuals or representatives of a group [15] .
7. Every study must be registered in a publicly accessible database before the start of data collection or data extraction. Study registration should include the study protocol [16] . 8. Sources of research funding must be made public at the time of study registration, in the study protocol and in the presentations of results, whether they are presented orally or in writing. All financial and non-financial public and private supports for the study should be documented. 9. Declarations of Interests of the study team members and external advisory committee must be made available at an early stage of the study, regularly updated and disclosed in the study report and in publications. 10. All comments received on the study protocol and study report that may impact the study outcome must be documented and made available to members of the study team, the study requester and the study funder. 11. The final study report should be uploaded into the publicly accessible database where the study is registered. 12. After completion of the final study report, study information should be made available to researchers from outside the study team in a collaborative approach. Such information may include the detailed study protocol (e.g. codes used for exposure and disease identification), the statistical analytical plan, programming codes, detailed interim and final results generated in the study and all comments received on the study protocol and study report that may impact the study outcome. Provision of this information should be based on a written request stating the purpose of the request. See also topic Sharing of study data. 13. In case of primary data collection, the subjects who participated in the study or their representatives are entitled to receive the main study results and the interpretation thereof.
Additional reading: [3, 12, 17, 18] 
Conflict of interest
Definition
Conflict of interest means a professional or personal interest sufficient to potentially influence the exercise of one's judgment regarding any activity of a research project.
Financial and commercial interests are the most easily identifiable sources of conflicts of interest, but conflicts can occur for other reasons, such as professional interest, personal or familial relationships, academic competition or beliefs. Recommendations 14. Actual or potential conflicts of interest must be identified and addressed at the planning phase of the study in order to limit any possible undue influence on its design and support the credibility of the study team and results. Perceptions of conflicts of interest are as important to be addressed as actual or potential ones. The research contract must include a description of the management of conflicts of interest. 15. The study team members should declare on a standard form all interests that may lead to potential conflicts. All Declarations of Interest must be made publicly available and must be updated in cases of a change.
Additional reading: [2,12,19]
Study protocol
Definition
Study protocol means a document containing the methodological details of the design, implementation, analysis, documentation and publication of the results of an epidemiological study. Recommendations 16. A protocol must be drafted as one of the first steps in any research project. It should demonstrate: the rationale for the study -that is, why the study should be conducted, given the current state of knowledge; the appropriateness of the proposed methods for testing the stated hypothesis, the methodological choices and why some of the possible options may have not been relevant or feasible; the feasibility of doing the study as proposed -that is, that the study can be completed successfully in the specified time and with the available resources; that the investigator(s) have the ability and skills to conduct the proposed study and are aware of limitations in the design; the provisions made to protect participants' personal data and meet legal requirements. 17. The study protocol must be developed by study team members with relevant expertise (i.e. clinical, epidemiological and statistical expertise and expertise on specific clinical or methodological aspects of the study; data privacy and ethics). 18. The process for reaching an agreement on design options should be agreed beforehand between the different persons involved. Internationally agreed guidelines should be consulted to ensure that all important aspects of the protocol have been covered. 19. The protocol must include a section with the ethical considerations involved and information regarding funding, institutional affiliations, potential conflicts of interest and actions taken for their management, data protection and any incentives for subjects. If applicable, the protocol must be approved by the relevant research ethics committee before the study commences. 20. The protocol must include a description of the contribution of each party to the study design, writing of protocol and the study work programme with information on milestones, data ownership, data access, study reports, publications and authorship. The protocol serves also as the reference document for contractual agreements between parties. 21. A specific section must describe the regulatory obligations and recommendations applicable to the study. 22 . A detailed draft protocol should undergo independent scientific review by experts that did not participate to its writing and are not anticipated to be directly involved in the study as investigators. Their recommendations are not binding but should be made available. 23. The study protocol should be registered in a publicly accessible register before the start of data collection or extraction. 24. The protocol may be amended as needed throughout the course of the study. Amendments to the protocol after the study start must be documented in a traceable and auditable way including the dates of the changes and the rationale for the changes. Changes to the protocol that may affect the interpretation of the study must be identifiable and reported as such in the study report and should be considered when interpreting the findings. This includes additions or amendments to the objectives or endpoints after the study start. The rationale for the change(s) to the protocol should be recorded with the protocol amendments or provided upon request once the study results have been published. 25. Key statistical analyses must be described in the study protocol. A detailed statistical analysis plan must be finalised before the end of data collection or extraction.
Additional reading: [3, 12, 16, 20, 21] 6. Study report
Study report means a document presenting the rationale, objectives, methods and results of the study, the interpretation and discussion of the results, including their strengths and limitations, and providing conclusions arising from the study.
Recommendations
26. The following principles must be followed for reporting results:
Interpretation of results is the responsibility of the study team exploiting the data and should acknowledge potential sources of errors and limitations of the study. Sensitivity analyses should be conducted to examine the effect of varying the study population inclusion/exclusion criteria, the assumptions regarding exposure, potential effects of misclassification, unmeasured confounders, and the definitions of potential confounders and outcomes on the association between the a priori exposure of interest and the outcome(s). Important safety concerns, even if based purely on subgroup analyses, must be documented and evaluated appropriately. Any deviations from the protocol or from the statistical analysis plan must be clearly documented in the report and a reasonable scientific explanation should be provided. Additional analyses which are deemed necessary based on initial results (e.g. formation of new sub-groups based on knowledge of (initial) study results) must always be presented as such. They must not be used for the purpose of verifying or rejecting the primary hypotheses stated in the protocol but can be used to generate further hypotheses.
Intermediate results of the study, i.e. preliminary or partial findings, analyses and conclusions formulated by the study team prior to the completion of the study, should be presented or published only subject to a procedure agreed in advance. the results of a study should undergo independent peer review before they are made public. 31. The research contract must allow the principal investigator and study team members to publish the study results independently from the funding or data source. The requester/funder must be entitled to view the results and interpretations included in the manuscript and provide comments prior to submission of the manuscript for publication. These non-binding comments should be made available. 32. In cases where the study is discontinued for any reason, any preliminary or partial results or conclusions should be presented or published and the results from a discontinued study must be identified as such. 33. Procedures must be put in place to rapidly inform regulatory and public health authorities of the results of the study, irrespective of the submission of a manuscript for publication.
Additional reading: [3, 16, [25] [26] [27] 8. Subject privacy
Definition
Privacy means the ability of an individual to be left alone, out of public view, and in control of information about oneself [28] .
Personal data are any information relating to an identified or identifiable natural person. An identifiable person is one who can be identified, directly or indirectly, in particular by reference to an identification number or to one or more factors specific to her/his physical, physiological, mental, economic, cultural or social identity [29] .
Recommendations 34. Privacy of study subjects in relation to personal data is a core principle of any medical research and divulgation of confidential personal data may have serious implications. In a study where personal/identifiable data are not needed or are not available (such as in a study with secondary data analysis), this should be stated in the protocol. 35. In case where personal data are collected or used in a study, the applicable legislation, in Europe Directive 95/46/EC, must be followed.
Additional reading: [2, 14, 27, 29] 9. Sharing of study data
Analytical data set means the minimum set of data required to perform the statistical analyses leading to the results for the primary objective(s) of the study [16] .
Recommendations 36. There should be an open and collaborative approach to sharing study data with persons from outside the study team. Data sharing will normally concern only the anonymised analytical dataset. 37. Data should be shared only after the study report has been finalised. 38. Sharing of study data must be based on a written request specifying the ground of the request, the nature of the data requested and a protocol on the analyses to be conducted. It is the responsibility of the study team to verify the compliance of the request with the data protection legislation and to seek approval or ask advice from concerned persons or committees, including, if relevant, the data controller, the data custodian and the ethics committee. 39. Requests for data sharing must be made on specific grounds with a justification based on public health interest, including: To corroborate the study results if there is evidence of conflicting results with different studies addressing the same research question, or in case of suspected methodological issues which might impact on the study outcome (such as the statistical analysis performed); To perform additional research based on the data, such as a patient-based meta-analysis, sub-group analyses, accounting for confounding factors, use of alternative statistical methods, or testing of new hypotheses with public health impact; In the context of an audit by a national competent authority. 40. The decision to share study data lies with the study team or a delegated appropriate committee. The public health objective of the request and the scientific quality of the protocol should be considered for the decision. 41. Analyses performed with shared data must follow the provisions of the ADVANCE Code of Conduct, including making available the request for data sharing and the response provided. The data requester may be asked for fair compensation for dataset preparation and analysis.
Additional reading: [12, 30] 
Research contract
Definition
Research contract means a written agreement between two or more parties involved in a research project, intended to be enforceable by law.
The research contract may have different objectives. It will set the terms and conditions of the collaboration between the parties for the conduct of the study, which can differ for each study. The research contract may set out the conditions under which, for example:
Funding is provided by a party or parties to other party or parties for a research project; Part of the research project is sub-contracted by a party to another one; Different parties agree to enter into a collaboration for a same project; The provider of primary data will give access to the data and allow their secondary use for a research project.
Recommendations 42. The research contract must never lead investigators or other entities, directly or indirectly, to violate the principles of the Helsinki Declaration for Medical Research [27] , or act against applicable legal or regulatory obligations. 43. Key elements of the research contract are clarity and transparency: all relevant aspects must be covered in a way that is understandable by all the parties concerned. 44. In cases where several parties interact in the study, a unique multipartite contract is preferred to support transparency and clarity on roles and responsibilities. In cases where several bipartite contracts need to be established for the same study, the terms of agreement should be communicated to the management entity of the study. 45. The research contract should indicate that the conduct of the study will follow the recommendations of the ADVANCE Code of Conduct and describe the following elements: scientific rationale, main objectives and brief description of the research to be carried out; the work to be undertaken and the tasks covered by the contract (with deliverables and milestones as appropriate and contingency plans if timelines cannot be met), as well as the roles and responsibilities of the different parties for their implementation; rights and obligations of each of the concerned entities communication plan for the scheduled progress and final reports; publication policy and authorship; intellectual property rights on the protocol and results; process for disclosure, update and management of potential conflicts of interests; transparency measures: which information will be made public, and how; provision regarding registration of the study and publication of the protocol; archiving of data, rights of data ownerships and access to data; storage and availability of analytical dataset and statistical programmes for regulatory audit and inspection;
